|MDACC Study No:||2005-0733 (clinicaltrials.gov NCT No: NCT00492050)|
|Title:||Primary Treatment of Waldenstrom's Macroglobulinemia with Bortezomib (Velcade®) and Rituximab followed by autologous stem cell collection|
|Principal Investigator:||Sheeba K. Thomas|
|Treatment Agent:||Bortezomib; Rituximab|
|Study Description:||The main goal of this clinical research study is to learn if Velcade ® |
(bortezomib) given with rituximab can help to control WM. This drug
combination will allow researchers to collect your stem cells in case it is
possible to transplant the stem cells as treatment if your WM gets worse.
Researchers will also look at the safety and tolerability of this drug
combination followed by treatment with other drug combinations.